Download free PDF

Urology Devices Market Size & Share 2026-2035

Report ID: GMI14397
   |
Published Date: November 2026
 | 
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:

Urology Devices Market Size

The urology devices market was valued at USD 38.8 billion in 2025 and is projected to reach USD 41.4 billion in 2026, advancing at a 6.2% CAGR (2026–2035) to USD 71.2 billion by 2035.

Urology Devices Market Key Takeaways

2025 Market Size
$ 38.8 Billion
2026 Market Size
$ 41.4 Billion
2035 Forecast Market Size
$ 71.2 Billion
CAGR (2026–2035)
6.2%
Regional Dominance
Largest Market
North America
Fastest Growing Region
Middle East & Africa
Key Players
  • Market Leader: Fresenius Medical Care led with over 16.3% market share in 2025.

  • Leading Players: Top 5 players in this market include Fresenius Medical Care, Baxter / Vantive, Boston Scientific, Intuitive Surgical, Olympus Corporation, which collectively held a market share of 42.4% in 2025.

The urology devices market is evolving from a capital-equipment-centered business toward a broader recurring-revenue model shaped by dialysis consumables, outpatient procedure volumes, and technologies that reduce dependence on hospital-based reprocessing and care delivery. Demand timing increasingly depends on the interaction between chronic renal disease management, ambulatory procedural capacity, reimbursement design, and the adoption of connected home-care platforms.

GMI Analyst View

Our discussions with device manufacturers and senior clinical procurement teams across major health systems indicate that the urology devices market generated approximately USD 36.4 billion in revenue in 2024, a performance that reflected both resilient consumable demand from growing dialysis patient volumes and accelerating capital investment in single-use endoscopic platforms ahead of the current forecast window.

Urology Devices Market Trends, Growth Drivers & GMI Forecast Outlook

The market's outlook rests on an unusually durable clinical-demand base: renal replacement therapy generates repeat consumable use, while stone management, bladder care, and minimally invasive treatment platforms are widening the settings in which urological procedures can be delivered. Growth remains sensitive to reimbursement capacity, modality adoption, and regulatory execution.

Key Drivers

DriverEvidence signalMarket-demand implicationGMI forecast condition
Expanding global burden of kidney failure requiring replacement therapyGlobal cases of kidney failure requiring replacement therapy reached 4.59 million in 2023, spanning patients on maintenance dialysis and those with a functioning kidney transplant [1]Rising patient counts extend recurring demand for hemodialysis machines, PD systems, CRRT equipment, and consumablesDialysis Devices segment is forecast to maintain the largest revenue share through 2035
High global CKD prevalence forming a sustained ESRD pipelineAn estimated 788 million adults aged 20 and older worldwide had chronic kidney disease in 2023, providing the primary upstream disease pipeline for dialysis device demand [2]Large and growing upstream CKD population sustains device demand across catheter, stent, PD, and early-stage renal access indicationsCKD-linked device demand is projected to expand throughout the forecast period
Regulatory clearance activity enabling single-use endoscope adoptionFDA and CE regulatory frameworks have established distinct clearance pathways for single-use flexible ureteroscopes and cystoscopes, with multiple OEMs achieving independent 510(k) and CE approvals for dedicated disposable platformsReduced reprocessing overhead, lower infection transmission risk, and on-demand device availability are accelerating adoption in ambulatory urology centersDisposable cystoscope and ureteroscope categories are projected to record the highest growth rates within the By Product dimension through 2035

Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.

The renal-care demand base is consequential because its economics are tied to recurring treatment rather than episodic procedure scheduling. Global all-age dialysis prevalence increased 104% between 1990 and 2023 [1], reinforcing the installed patient base that supports regular requirements for dialyzers, tubing, concentrates, access products, and therapy-support equipment. This recurring utilization provides manufacturers with a more stable demand layer than elective capital replacement cycles.

The clinical pipeline also extends beyond patients already receiving renal replacement therapy. Chronic kidney disease screening, earlier referral patterns, and renal-access planning can increase demand for catheter, stent, monitoring, and home-care technologies before a patient reaches advanced kidney failure. Meanwhile, single-use endoscopy changes the commercial equation for providers by transferring part of the value proposition from asset maintenance and sterilization infrastructure to per-procedure availability, infection-control assurance, and scheduling flexibility.

Key Restraints

RestraintEvidence signalMarket-demand implicationGMI forecast condition
High per-patient cost of kidney replacement therapy limiting dialysis accessAnnual median hemodialysis cost per patient reached USD 19,380 across surveyed countries, well above what most lower-income health systems can sustain at population scale [3]Cost-driven access barriers suppress device volume intensity in sub-Saharan Africa, South Asia, and parts of Latin AmericaMEA and select lower-income Asia Pacific markets are forecast to record above-average revenue growth rates from compressed base intensities
Structural underutilization of peritoneal dialysis in major economiesPeritoneal dialysis accounts for fewer than 3% of prevalent dialysis patients in major economies including Japan, Brazil, and Poland [4]Despite lower infrastructure requirements and favorable home-care economics, PD modality penetration remains a fraction of the treatable dialysis populationPD Systems & Supplies segment is projected to expand at above-market rates through 2035, though hemodialysis will continue to dominate dialysis device revenue
Regulatory complexity and extended clearance timelines for novel urology devicesEU Medical Device Regulation and FDA's 510(k) and PMA frameworks require rigorous clinical evaluation, technical documentation packages, and ongoing post-market surveillance reporting for novel and high-risk urology device classificationsExtended market-entry timelines and rising regulatory compliance costs concentrate product launches among established OEMsRegulatory alignment across the US, EU, and key Asia Pacific jurisdictions is expected to sustain selective barriers to new market entry, reinforcing tier-one incumbents through 2035

Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.

Dialysis affordability creates a divide between disease burden and realized device demand. Where public reimbursement, private insurance, or established provider networks can fund therapy, manufacturers can support high utilization of sophisticated equipment and consumables. In resource-constrained settings, the same underlying renal disease burden may translate into delayed treatment initiation, lower treatment intensity, or restricted access to capital-intensive modalities. This limits addressable spending even as long-term patient need rises.

Peritoneal dialysis presents a separate constraint rooted in care-pathway design and institutional habits. Established hemodialysis networks, clinician training requirements, patient self-management expectations, and reimbursement frameworks can discourage modality conversion even where home care could relieve clinical-center capacity. Regulatory requirements add another layer of friction for novel endoscopes, robotic systems, and therapeutic platforms, favoring companies with established quality systems, clinical-evidence capabilities, and post-market infrastructure.

GMI Analyst View

We view the forecast as a contest between predictable renal-care consumption and the less linear adoption of advanced procedural platforms. Dialysis-related demand supplies resilience, while outpatient migration, disposable endoscopy, and home-care adoption determine where incremental value accrues. Reimbursement architecture will remain the main separator between markets that expand access and those that simply replace installed equipment.

Urology Devices Market Segment Analysis

By Product

The urology devices market's product mix is anchored by chronic renal-care equipment and consumables, but its higher-growth opportunities are increasingly tied to procedure-enabling technologies that support ambulatory treatment, infection-control priorities, and lower-friction clinical workflows.

Urology Devices Market Size By Product 2025 And 2035 Usd Billion
Urology Devices Market Size By Product 2025 And 2035 Usd Billion

Dialysis Devices generated USD 23.28 billion in 2025 and are projected to reach USD 40.89 billion by 2035. The category's scale reflects the combination of capital equipment, frequent consumable use, water-treatment requirements, and therapy infrastructure required across renal replacement settings. Demand is increasingly shaped by the balance between in-center care, acute care, and home-capable treatment models.

HD Machines & Consumables generated USD 17.46 billion in 2025 and are expected to advance at a 5.4% CAGR (2026–2035). The sub-segment retains a broad installed base because treatment frequency sustains routine demand for dialyzers, bloodlines, concentrates, and related supplies. In mature markets, replacement cycles and service reliability matter alongside volume growth, while developing treatment networks require both equipment placement and dependable consumable supply chains.

PD Systems & Supplies are projected to reach USD 7.71 billion by 2035, advancing at a 7.0% CAGR (2026–2035). The growth profile reflects the strategic appeal of home-based treatment where providers and payors seek to reduce pressure on in-center capacity. Adoption depends on patient selection, clinician confidence, connected monitoring, logistics for supplies, and reimbursement arrangements that recognize the value of home-based renal care.

CRRT/AKI Devices generated USD 1.94 billion in 2025 and are expected to grow at a 6.3% CAGR (2026–2035). Critical-care utilization links this category to intensive-care capacity, acute kidney injury management protocols, and hospital investment in high-acuity services. Its demand pattern differs from maintenance dialysis because it is driven by severity of illness, clinical workflow, and availability of specialized personnel.

Endoscopes are projected to reach USD 10.39 billion by 2035, expanding at a 7.3% CAGR (2026–2035). The category benefits from the migration of diagnostic and therapeutic procedures toward settings that value rapid turnaround, reliable scope availability, and a lower reprocessing burden. Product choice is increasingly influenced by total procedure economics rather than acquisition cost alone.

Cystoscopes — Disposable generated USD 1.16 billion in 2025 and are expected to advance at a 10.6% CAGR (2026–2035). Disposable systems are gaining relevance in diagnostic, surveillance, and office-based procedures where immediate availability and reduced reprocessing exposure can alter workflow economics. Their commercial appeal is strongest where clinicians and administrators value predictable procedure readiness over extending the life of reusable assets.

Cystoscopes — Reusable are projected to reach USD 1.99 billion by 2035, advancing at a 2.5% CAGR (2026–2035). Reusable devices remain relevant in facilities with established sterilization capacity, high utilization, and capital-preservation priorities. However, the category faces greater procurement scrutiny as providers compare maintenance, repair, turnaround time, and contamination-control requirements against disposable alternatives.

Ureteroscopes — Disposable are projected to reach USD 4.20 billion by 2035 and are expected to expand at a 10.2% CAGR (2026–2035). Their adoption is supported by stone-management procedures that require reliable access, consistent image quality, and availability across scheduling peaks. The shift also enables facilities with limited scope-reprocessing resources to broaden ureteroscopic capability.

Ureteroscopes — Reusable generated USD 776 million in 2025 and are expected to grow at a 1.5% CAGR (2026–2035). Their installed base remains meaningful, particularly where facilities have experienced staff, dedicated maintenance systems, and high procedure density. Yet repair exposure and downtime can make reusable platforms less attractive in settings where procedural throughput and access-on-demand carry greater operational value.

Laser & Lithotripsy generated USD 2.71 billion in 2025 and are projected to advance at a 6.8% CAGR (2026–2035). The segment is supported by demand for minimally invasive stone management and ongoing technology upgrades in laser performance, fragmentation efficiency, and procedural precision. Capital decisions increasingly reflect the ability of platforms to support a broad procedural mix and integrate with ambulatory workflows.

Other Products & Accessories are projected to reach USD 14.56 billion by 2035, advancing at a 6.4% CAGR (2026–2035). This broad category captures a diversified set of procedure-linked, chronic-care, and implantable technologies. Its demand profile is therefore less dependent on a single clinical pathway and more exposed to shifts in urological procedure mix, patient follow-up needs, and specialty-care capacity.

Catheters & Ureteral Stents generated USD 3.49 billion in 2025 and are expected to grow at a 5.0% CAGR (2026–2035). Demand is underpinned by routine upper-tract access, drainage management, postoperative care, and chronic catheter-dependent conditions. Product differentiation centers on placement reliability, patient comfort, infection prevention, and ease of use across hospital and outpatient environments.

BPH Devices are projected to reach USD 1.67 billion by 2035, expanding at a 7.9% CAGR (2026–2035). Minimally invasive therapies are gaining ground where patients and providers seek symptom relief with shorter recovery periods and less dependence on operating-room resources. Adoption is supported by the ability to move selected benign prostatic hyperplasia procedures into office or ambulatory settings.

Incontinence & Men's Health Devices generated USD 1.16 billion in 2025 and are expected to advance at a 5.9% CAGR (2026–2035). The category is influenced by specialist referral pathways, long-term management needs, and growing use of implantable and neuromodulation-based treatment options. Commercial success depends on physician training, patient selection, follow-up infrastructure, and evidence of durable outcomes.

Robotic Urology Systems are projected to reach USD 3.15 billion by 2035, expanding at a 10.3% CAGR (2026–2035). Demand reflects the spread of robotic-assisted procedures beyond leading academic centers into broader hospital networks. Procedure standardization, surgeon training, instrument utilization, and the availability of hospital capital all influence the rate at which robotics becomes embedded in urological care pathways.

By Application

Kidney Diseases (CKD/ESRD) generated USD 20.17 billion in 2025 and are expected to grow at a 5.8% CAGR (2026–2035). This application remains structurally important because renal replacement therapy combines chronic patient management with repeat device and consumable requirements. Its revenue base is resilient, although the pace of expansion is shaped by access, modality mix, and the ability of health systems to fund long-duration care.

Urolithiasis is projected to reach USD 10.89 billion by 2035, advancing at a 7.1% CAGR (2026–2035). Stone management supports demand across ureteroscopes, access devices, laser systems, and lithotripsy platforms. Its growth is reinforced by the clinical preference for minimally invasive treatment and the increasing feasibility of delivering procedures in ambulatory environments.

Urethral Malignancies generated USD 4.65 billion in 2025 and are expected to expand at a 6.7% CAGR (2026–2035). Ongoing surveillance, diagnostic evaluation, endoscopic intervention, and treatment follow-up create recurring device use across this care pathway. Providers' ability to manage surveillance efficiently can increase the strategic importance of flexible endoscopy and procedure-ready disposable technologies.

Bladder Disorders are projected to reach USD 6.95 billion by 2035, advancing at a 6.0% CAGR (2026–2035). The application encompasses a mix of diagnostic, therapeutic, and long-term management needs, including technologies for overactive bladder and urinary retention. Growth depends on broader specialist access, diagnosis rates, and the acceptance of device-enabled alternatives to medication-only treatment.

Erectile Dysfunction generated USD 1.94 billion in 2025 and is expected to grow at a 5.5% CAGR (2026–2035). Demand is supported by patients for whom pharmacological treatment does not provide a sufficient clinical outcome. The segment relies on specialist capability, patient counseling, reimbursement conditions, and evidence supporting device durability and quality-of-life benefits.

Other Applications are projected to reach USD 5.60 billion by 2035, advancing at a 7.3% CAGR (2026–2035). This group includes urodynamic testing, acute-care applications, and emerging urology-adjacent needs that broaden the market's clinical exposure. Its performance reflects the continuing integration of monitoring, diagnostic, and therapeutic technologies across specialty-care settings.

By End Use

Hospitals & Clinics generated USD 20.17 billion in 2025 and are expected to expand at a 5.7% CAGR (2026–2035). These settings remain central to complex procedures and high-acuity care, including advanced endoscopy, robotics, laser intervention, and critical-care renal therapy. Their purchasing decisions are influenced by capital budgeting, procedure volumes, clinical staffing, and the need to maintain broad service-line capability.

Urology Devices Market Share By End Use 2025
Urology Devices Market Share By End Use 2025

Dialysis Centers are projected to reach USD 23.64 billion by 2035, advancing at a 5.4% CAGR (2026–2035). Dedicated providers concentrate high-frequency consumable demand and can exert substantial purchasing influence through standardized procurement across clinic networks. Operational efficiency, supply continuity, service support, and modality availability are key factors in vendor selection.

Home Care accounted for 12.0% of the market in 2025 and is projected to reach USD 12.47 billion by 2035. The channel's expansion reflects health-system interest in shifting appropriate care away from clinical centers while improving patient autonomy. Connected peritoneal dialysis platforms, portable supplies, and remote monitoring are important enablers, but growth requires provider training, patient support, and reliable logistics.

GMI Analyst View

We see the strongest strategic differentiation arising where device design removes a bottleneck in care delivery. Products that reduce sterilization dependence, support remote monitoring, or allow a procedure to move into an ambulatory setting are not merely substituting technologies; they are changing who can provide care, where it can occur, and how capacity is monetized.

Urology Devices Market Regional Analysis

Urology Devices Market Share By Region 2025 And 2035
Urology Devices Market Share By Region 2025 And 2035

North America Urology Devices Market Analysis

The urology devices market in North America generated USD 13.19 billion in 2025 and is projected to reach USD 21.84 billion by 2035. The region combines intensive renal-care utilization with mature hospital procurement, extensive dialysis-provider infrastructure, and broad access to advanced endoscopic and robotic procedures. Its growth is increasingly determined by modality changes and outpatient migration rather than by greenfield infrastructure alone.

United States

The United States generated USD 11.64 billion in 2025 and is projected to reach USD 19.18 billion by 2035. The market is supported by a substantial outpatient dialysis network and deep clinical adoption of advanced procedural platforms. Adjusted ESRD incidence declined 18.6% over the preceding decade through 2022 [4], moderating new-patient growth while leaving the installed treatment population and its associated consumable demand significant. Value-based reimbursement and home-care initiatives continue to influence procurement priorities.

Canada

Canada is projected to reach USD 2.65 billion by 2035 and is expected to grow at a 5.4% CAGR (2026–2035). Provincial procurement structures can support predictable purchasing cycles for renal-care systems and consumables. Continued interest in peritoneal dialysis and outpatient care is expected to favor technologies that help providers manage capacity while maintaining care continuity.

Europe Urology Devices Market Analysis

Europe generated USD 9.7 billion in 2025 and is expected to advance at a 5.4% CAGR (2026–2035). Established renal-care infrastructure, device-regulation compliance requirements, and selective adoption of single-use endoscopes shape the regional market. Providers are balancing the economics of reusable assets with infection-control expectations, labor constraints, and procedure-throughput objectives.

Germany

Germany generated USD 2.32 billion in 2025 and is expected to grow at a 5.3% CAGR (2026–2035). Its established hospital and dialysis infrastructure supports substantial equipment and consumable demand. The country's manufacturing base and clinical capability also make it an important environment for technology adoption, service support, and procurement of high-specification urology systems.

United Kingdom

The United Kingdom is projected to reach USD 2.57 billion by 2035 and is expected to advance at a 5.2% CAGR (2026–2035). Demand is influenced by public-sector purchasing, pressure to improve procedural throughput, and the continued expansion of care beyond major teaching hospitals. Disposable technologies can be particularly relevant where they simplify logistics and improve scope availability.

France

France generated USD 1.16 billion in 2025 and is expected to grow at a 5.1% CAGR (2026–2035). Public hospital systems remain important purchasers of renal-care equipment and procedure-linked technologies. Specialist urology centers contribute to adoption of endoscopy and laser platforms where clinical volume and training support advanced intervention.

Spain

Spain is projected to reach USD 1.33 billion by 2035 and is expected to advance at a 5.5% CAGR (2026–2035). The market benefits from sustained renal-care capacity and gradual attention to the workflow advantages of disposable endoscopy. Public-system procurement decisions will remain influential in determining the speed at which new procedural platforms diffuse across hospitals.

Italy

Italy generated USD 776 million in 2025 and is expected to grow at a 5.6% CAGR (2026–2035). Renal-care requirements sustain recurring consumable demand, while academic and specialty hospitals continue to influence uptake of advanced surgical technologies. The market's mix of regional health systems makes local procurement practices important to technology penetration.

Netherlands

The Netherlands is projected to reach USD 651 million by 2035 and is expected to advance at a 5.3% CAGR (2026–2035). Its emphasis on outpatient and home-based care supports the relevance of peritoneal dialysis, home hemodialysis, and office-compatible urology technologies. Care-delivery design, rather than hospital-capital intensity alone, is likely to guide product adoption.

Asia Pacific Urology Devices Market Analysis

Asia Pacific is projected to reach USD 24.71 billion by 2035 and is expected to expand at a 7.4% CAGR (2026–2035). The region's opportunity combines dialysis-infrastructure investment in emerging markets with advanced technology adoption in developed health systems. Local manufacturing, public reimbursement expansion, and growing capacity for specialist procedures will determine how quickly demand shifts from essential renal-care equipment to higher-value therapeutic platforms.

China

China generated USD 4.26 billion in 2025 and is expected to grow at an 8.2% CAGR (2026–2035). Dialysis-center development, increasing chronic-disease diagnosis, and domestic manufacturing capability support broad-based demand. The market's scale also creates room for lower-cost flexible endoscopy and renal-care technologies to reach community settings that have historically had limited access to advanced urological procedures.

Japan

Japan is projected to reach USD 4.12 billion by 2035 and is expected to advance at a 4.3% CAGR (2026–2035). A mature renal-care system and an aging population support steady demand, although market maturity moderates headline growth. Japan remains important for advanced laser, endoscopy, and dialysis innovations that can improve clinical productivity or reduce treatment burden.

India

India generated USD 1.55 billion in 2025 and is expected to expand at a 10.2% CAGR (2026–2035). Growth is supported by expanding private dialysis networks, broader insurance coverage, and rising diagnosis of renal and stone disease. The market requires suppliers to balance affordability with service reach, local training, and dependable consumable distribution.

South Korea

South Korea is projected to reach USD 2.13 billion by 2035 and is expected to advance at a 6.2% CAGR (2026–2035). Strong technology adoption and a developed reimbursement environment support demand for advanced surgical, laser, and endoscopic platforms. Providers' appetite for efficiency and clinical differentiation can accelerate adoption of newer therapeutic technologies.

Australia

Australia generated USD 776 million in 2025 and is expected to grow at a 5.2% CAGR (2026–2035). Policy support for home-based care and a well-developed clinical infrastructure strengthen demand for connected renal-care technologies. The market offers a relevant test case for suppliers seeking to demonstrate the operational value of home dialysis and decentralized patient support.

Latin America Urology Devices Market Analysis

Latin America generated USD 1.94 billion in 2025 and is expected to advance at a 7.2% CAGR (2026–2035). Demand is shaped by expanding dialysis-provider networks, evolving health coverage, and a gradual increase in endoscopic and stone-management capacity. Economic volatility and uneven public funding remain important constraints on the pace of capital-equipment investment.

Brazil

Brazil generated USD 776 million in 2025 and is expected to grow at a 7.2% CAGR (2026–2035). Its broad renal-care need and established public health infrastructure create ongoing demand for dialysis technologies and consumables. Local supply-chain depth and provider-network development will be important in sustaining access across a geographically diverse patient population.

Mexico

Mexico is projected to reach USD 742 million by 2035 and is expected to expand at a 6.7% CAGR (2026–2035). Private healthcare investment, evolving dialysis coverage, and proximity to North American supply chains support market development. Demand growth will depend on the ability of providers to expand specialist care while managing affordability pressures.

Argentina

Argentina generated USD 194 million in 2025 and is expected to advance at a 6.2% CAGR (2026–2035). Established clinical infrastructure supports ongoing consumable demand, even when macroeconomic conditions complicate large capital purchases. Suppliers that can support continuity of care and flexible procurement arrangements may be better positioned in this environment.

Middle East & Africa Urology Devices Market Analysis

Middle East & Africa is projected to reach USD 4.25 billion by 2035 and is expected to grow at an 8.2% CAGR (2026–2035). The region's outlook is driven by healthcare-capacity investment, rising metabolic disease burden, and divergent purchasing conditions between well-funded Gulf markets and resource-constrained African health systems. Demand will depend on whether infrastructure expansion translates into durable treatment access and service capability.

Saudi Arabia

Saudi Arabia generated USD 582 million in 2025 and is expected to advance at an 8.6% CAGR (2026–2035). Investment in hospital capacity, specialist services, and health-sector transformation supports demand for renal-care, endoscopic, and robotic technologies. Procurement increasingly reflects the ambition to develop higher-acuity domestic clinical capability.

United Arab Emirates

The United Arab Emirates is projected to reach USD 930 million by 2035 and is expected to grow at a 9.1% CAGR (2026–2035). Premium-care positioning and investment in specialized hospital infrastructure support adoption of advanced urology capital equipment. The market's growth is linked to chronic-disease management, clinical differentiation, and the development of regional referral capability.

South Africa

South Africa generated USD 194 million in 2025 and is expected to advance at a 6.6% CAGR (2026–2035). The country remains an important distribution and service base for sub-Saharan markets, although public-sector funding constraints limit broader dialysis access. Private hospital expansion supports demand for selected advanced technologies and recurring renal-care consumables.

GMI Analyst View

We expect regional strategy to become less about simply entering high-growth geographies and more about matching product design to care-delivery capacity. Mature markets reward workflow innovation and modality shifts, while emerging markets require credible approaches to affordability, service coverage, and clinician training. Suppliers able to serve both premium and access-oriented demand pools should have the strongest strategic flexibility.

Urology Devices Market Share & Competitive Landscape

The urology devices market share structure is moderately concentrated, with the top five companies collectively accounting for approximately 42.4% of global revenue in 2025. Competitive advantage is determined by more than product breadth: leading participants combine installed-base relationships, recurring consumable portfolios, regulatory resources, clinical education, and the capacity to serve hospitals, dialysis providers, and outpatient care settings through different commercial models.

Fresenius Medical Care

held a 16.3% share in 2025. Its leadership reflects deep exposure to hemodialysis equipment and consumables, as well as the strategic benefit of operating within a broad renal-care delivery ecosystem. Vertical integration can strengthen institutional relationships and provide visibility into clinical workflow needs, although it also increases the importance of maintaining supply continuity and service quality across markets.

Baxter/Vantive

held a 10.1% share in 2025. Its kidney-care portfolio spans hemodialysis, peritoneal dialysis, and critical-care renal replacement technologies, positioning the company across multiple treatment modalities. The dedicated Vantive business model sharpens strategic focus on renal care, where home-treatment capability, provider partnerships, and dependable consumable logistics are central competitive factors.

Boston Scientific

held a 6.2% share in 2025. The company's urology position combines stone-management systems, single-use flexible endoscopy, access products, and continence technologies. Its portfolio breadth enables participation in both procedural growth areas and chronic-condition management, while the commercial challenge is to integrate specialized technologies into coherent physician, hospital, and ambulatory-care value propositions.

Intuitive Surgical

participates through the portion of robotic-system placements, instruments, and procedures attributable to urological indications. Its position is supported by the expansion of robotic-assisted surgery, but adoption remains dependent on hospital capital capacity, surgeon training, procedure volumes, and evidence that robotic workflows can be sustained outside leading academic centers.

Olympus Corporation

competes through therapeutic flexible endoscopy, stone-management technologies, and related procedural devices. Its market position benefits from established endoscopy relationships and from the growing interest in single-use urology platforms, where distribution capability, physician familiarity, and product availability can be as important as device specifications.

Recent Industry Developments

Olympus-MacroLux Distribution Agreement (September 2025): Olympus announced an exclusive global distribution agreement with MacroLux Medical Technology Co., Ltd. for single-use cystoscopes, ureteroscopes, and suction access sheaths across markets including the United States, Canada, Europe, China, South Korea, and Australia [5]. The agreement broadens Olympus's disposable urology offering and strengthens its ability to address procedure settings seeking flexible instrument availability without reprocessing dependence.

Boston Scientific Closes Axonics Acquisition (November 2024): Boston Scientific completed its acquisition of Axonics, Inc., expanding its continence and neuromodulation portfolio with technologies for overactive bladder and urinary retention [6]. The transaction reinforces the strategic value of integrated offerings that extend beyond stone management into chronic bladder-condition treatment pathways.

Fresenius Medical Care Divests Spectra Laboratories Assets (February 2025): Fresenius Medical Care announced an agreement to divest select Spectra Laboratories assets to Quest Diagnostics while establishing a related service arrangement for laboratory support to its U.S. dialysis operations [7]. The move reflects continued portfolio discipline around core renal-care delivery and device-related capabilities.

Need a specific section of this report?

Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.


Authors:  Monali Tayade, Sampada Kulkarni

Frequently Asked Questions (FAQs):

The urology devices market size was estimated at USD 38.8 billion in 2025 and is expected to reach USD 41.4 billion in 2026.
The market is projected to reach USD 71.2 billion by 2035, growing at a CAGR of 6.2% from 2026 to 2035.
North America currently holds the largest share of the urology devices market in 2025.
Middle East & Africa is projected to be the fastest-growing region during the forecast period.
Some of the major players in urology devices market include Fresenius Medical Care, Baxter / Vantive, Boston Scientific, Intuitive Surgical, Olympus Corporation.

Research methodology, data sources & validation process

This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.

Our 6-step research process

  1. 1. Research design & analyst oversight

    At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.

    Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.

  2. 2. Primary research

    Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.

  3. 3. Data mining & market analysis

    Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.

  4. 4. Market sizing

    Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.

  5. 5. Forecast model & key assumptions

    Every forecast includes explicit documentation of:

    • ✓ Key growth drivers and their assumed impact

    • ✓ Restraining factors and mitigation scenarios

    • ✓ Regulatory assumptions and policy change risk

    • ✓ Technology adoption curve parameter

    • ✓ Macroeconomic assumptions (GDP growth, inflation, currency)

    • ✓ Competitive dynamics and market entry/exit expectations

  6. 6. Validation & quality assurance

    The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.

    Our triple-layer validation process ensures maximum data reliability:

    • ✓ Statistical Validation

    • ✓ Expert Validation

    • ✓ Market Reality Check

Trust & credibility

10+
Years in Service
Consistent delivery since establishment
A+
BBB Accreditation
Professional standards & satisfaction
ISO
Certified Quality
ISO 9001-2015 Certified Company
150+
Research Analysts
Across 20+ industry verticals
95%
Client Retention
5-year relationship value

Verified data sources

  • Trade publications

    Industry journals, trade publications, and specialized media.

  • Industry databases

    Proprietary and third-party market databases

  • Regulatory filings

    Government procurement records and policy documents

  • Academic research

    University studies and specialist institution reports

  • Company reports

    Annual reports, investor presentations, and filings

  • Expert interviews

    C-suite, procurement leads, and technical specialists

  • GMI archive

    13,000+ published studies across 20+ industry verticals

  • Trade data

    Import/export volumes, HS codes, and customs records

Parameters studied & evaluated

Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →

Authors:  Monali Tayade, Sampada Kulkarni
We use cookies to enhance user experience. (Privacy Policy)